新型多靶点酪氨酸激酶抑制剂苏尼替尼的研究进展

Sunitinib: a novel multitargeted receptor tyrosine kinase inhibitor

苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。临床前研究及临床研究证实该药对多种实体肿瘤有明显的抗肿瘤活性,包括肾细胞癌、胃肠道间质瘤、神经内分泌肿瘤、肉瘤、甲状腺癌、黑色素瘤、乳腺癌、结直肠癌和非小细胞肺癌,尤其是对晚期肾细胞癌和伊马替尼耐受的胃肠道间质瘤的治疗取得显著的疗效。药物不良反应主要为轻度的乏力、恶心和血小板减少。现就该药近年来的研究进展作一简要的介绍。

Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. The preclinical and clinic trials have demonstrated that sunitinib owns potent antitumor effects in many solid tumors, including renal cell carcinoma, gastrointestinal stromal tumour, neuroendocrine tumor, sarcoma, carcinoma of thyroid, melanoma, breast carcinoma, colorectal cancer and nonsmall-cell lung cancer, especially in the therapy of advanced renal cell carcinoma and imatinib resistant gastrointestinal stromal tumour. The main adverse reactions include hypodynamia, nausea and thrombocytopenia. This paper reviews R＆D progresses of sunitinib.